Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3

(2010) C. P. Guise et al.   CANCER RESEARCH

Hypoxia-activated prodrugs in cancer therapy: progress to the clinic

(2010) William A Denny   Future Oncology

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors

(2009) Michael B. Jameson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity

(2009) R. S. Singleton et al.   CANCER RESEARCH

Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs, and Humans

(2009) Y. Gu et al.   DRUG METABOLISM AND DISPOSITION

The hematopoietic stem cell niche: Low in oxygen but a nice place to be

(2009) Pernilla Eliasson et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Rapid and sensitive ultra-high-pressure liquid chromatography–tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: Application to a pharmacokinetic study

(2009) Yongchuan Gu et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Noninvasive Molecular Imaging of Hypoxia in Human Xenografts: Comparing Hypoxia-Induced Gene Expression with Endogenous and Exogenous Hypoxia Markers

(2008) F. He et al.   CANCER RESEARCH

Molecular Characterization of the Pediatric Preclinical Testing Panel

(2008) G. Neale et al.   CLINICAL CANCER RESEARCH

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

(2007) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER